DSIP is a nine-amino-acid molecule whose chemistry is settled and whose biology is not. It was named in 1977 for the electroencephalographic effect its discovery assay measured, and in the decades since, no gene, precursor protein, or receptor has been reported for it. The distance between a well-defined synthetic compound and an unconfirmed physiological story is the whole subject here, and it is why no medicines regulator has approved the peptide for anything.
DSIP is a synthetic nonapeptide with the sequence Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu and a molecular weight of roughly 849 daltons, first purified and sequenced in 1977, for which no precursor gene, no cloned receptor, and no regulatory approval has ever been established.
The composition of this peptide explains most of the trouble that came later. Nine residues, three of them glycine, no basic groups and no disulfide bonds leave a floppy, acidic, unprotected chain carrying nothing distinctive on its surface. That profile makes the molecule routine to synthesize and unusually hard to detect specifically, which is the combination that has kept the field's central questions open.
The molecule is a linear nonapeptide, Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu, carrying a net charge near minus two at pH 7.4, with three of its nine residues glycine and no cysteines, glycosylation, or ring structure shielding the backbone from proteases.
The isolation was not a discovery moment; it was the endpoint of a programme that had already run for over a decade on a single assay. Its premise was the humoral theory of sleep, that a sleep-driving substance accumulating in blood should transfer from a sleeping animal to a waking one. Everything the field later claimed for this molecule rests on how well that assay isolated what it was tracking.
Thirteen years separated the 1964 Science report of a transferable delta-promoting factor from the 1977 Proceedings of the National Academy of Sciences paper giving its sequence, and the bioassay-guided design of that purification establishes only that activity and material travelled together through the columns.
The name records what the discovery assay measured, not what the molecule was later shown to do. Delta activity is the high-amplitude oscillation of roughly 0.5 to 4 hertz that dominates the deepest stage of non-rapid-eye-movement sleep, recipient rabbits showed more of it, and labelling the agent for the effect that found it was reasonable shorthand in 1977. What a reader meets today is a conclusion the literature never delivered, arriving before any evidence is examined.
| Criteria | What the name asserts | What the record reports |
|---|---|---|
| Effect on sleep | Induction of delta sleep | Human work thin and inconsistent; several small studies found no reliable change |
| Evidence base | Established pharmacology | A single bioassay in one species |
| Specificity | Sleep-specific action | Stress and thermoregulatory modulation, analgesia, opioid withdrawal also attributed |
| Revisability | A chemical descriptor | An unverified hypothesis fixed in the literature |
The name was assigned from a single rabbit bioassay rather than from confirmed pharmacology, and the human literature remains thin and inconsistent, with several small studies reporting no reliable change in sleep architecture.
No, and this absence is the most consequential gap in the entire subject. Endogenous peptides are cut out of larger precursor proteins encoded by identifiable genes, processed by known enzymes, packaged and released under regulation, and that chain is what separates a signalling molecule from a laboratory curiosity. The human genome has been sequenced and searchable for over two decades with no gene reported encoding a precursor that contains WAGGDASGE where known processing enzymes would liberate it.
Measured against the conventional checklist for accepting an endogenous neuropeptide, which asks for an identified precursor gene, demonstrated processing and regulated release, a specific receptor, and a physiological action a selective antagonist abolishes, this sequence satisfies none of the four.
Published reports place the signal across the central nervous system, peripheral organs and body fluids, which at face value reads as a broadly deployed signalling molecule and supplies most claims that the peptide is a real physiological participant. The qualifier attached to every one of those findings is where the reading collapses: the phrase is not DSIP, it is DSIP-like immunoreactivity, the field's own acknowledgement that what an antibody bound was measured rather than the peptide identified.
Every reported site rests on antibody assays of an analyte with no basic groups, a third of its sequence glycine and no structure, and confirmation by an orthogonal method establishing exact sequence and mass is largely absent from the record.
Badly, and the pattern of failure carries more information than any single negative result. Animal work after the original reports split, with some groups observing modest increases in slow-wave sleep and others finding nothing, showing the species, dose and timing sensitivity that usually marks a fragile finding rather than a robust pharmacology. The human trials were few and small, spread across intravenous, subcutaneous and intranasal routes, which leaves a null result impossible to separate from a dose that never reached a relevant compartment.
The replication record is a body of underpowered, methodologically inconsistent, decades-old work that failed to converge, and citing it in support of the peptide as an established sleep agent goes well past what it can carry.
Judging this work fairly means remembering what sat on the bench in 1977. Sequencing meant Edman degradation, reading residues one at a time from the amino terminus and consuming nanomole quantities of highly purified material to do it, and peptide mass spectrometry was not routine, so nothing independently confirmed that the material's mass matched the sequence proposed for it. The lasting problem is not the old equipment; the methods capable of settling the identity question have existed for years, and no re-isolation has been published.
The original 1977 identification has never been confirmed by methods capable of confirming it, since liquid chromatography coupled to tandem mass spectrometry would settle the question from a fraction of the material and no published re-isolation has appeared.
No medicines regulator has approved this peptide for any indication, and that is not a paperwork delay. There is no marketing authorization from the United States Food and Drug Administration, none from the European Medicines Agency, and none from any comparable national authority, which leaves no approved indication, no approved dose, no established route, no product labelling and no pharmacopoeial monograph defining what an acceptable batch consists of. Research-use-only labelling is routinely misread as a quality grade when it is the opposite: a statement that material is supplied for laboratory work and explicitly not for administration to humans.
| Criteria | An approved medicine | This peptide |
|---|---|---|
| Marketing authorization | FDA, EMA or comparable authority | None anywhere |
| Dose and route | Defined and labelled | None established |
| Batch standard | Pharmacopoeial monograph | No monograph; research-use-only obliges the seller to nothing |
| Mechanism of action | Characterized molecular target | No precursor gene or receptor, so no target to state |
| Supply chain | Regulated channel | Independent testing has found contents diverging from labels |
The peptide holds no marketing authorization from the FDA, the EMA, or any comparable national authority, and material sold under research-use-only labelling carries no assured identity, purity, or dose accuracy, with independent testing of peptides sold this way finding incorrect quantities, degradation products, and contaminants.
Educational use only. This article describes what the published scientific and clinical literature reports about Delta sleep-inducing peptide (DSIP). It is not medical advice, and it does not recommend, prescribe, or tell anyone to use anything described here. The regulatory status shown at the top of this page reflects what the record showed on the date given there and can change. mdpep.com does not sell any substance described here, does not endorse human use of it, and does not direct anyone to obtain it.
This is not guidance for your situation. Nothing here accounts for your medical history, your current medications, or anything else specific to you, and none of it should be used to make a decision about your own health.
Affiliate disclosure. Some links on this site are affiliate links, and mdpep.com may earn a commission when they are used. That never affects what is written here, it is not an endorsement of any vendor, and it is not a statement that anything described on this page is available to buy.
Every claim here ties to a named primary source and a date, written as plain documentation with nothing for sale. That is how MD PEP covers the whole peptide market.
